Consulta pública de la Comisión Europea sobre la Estrategia de la UE en materia de drogas 2013-2020
Esta estrategia presenta un marco político y una serie de prioridades de acción en el ámbito de las políticas de drogas en la UE. Más información, en inglés, está disponible abajo.
Suscríbase a las Alertas mensuales del IDPC para recibir información sobre cuestiones relacionadas con políticas sobre drogas.
Title
Public consultation for the 2016 evaluation of the EU Drugs Strategy and Action Plan on Drugs
Policy field(s)
Home Affairs; Anti-drugs; Public health
Target group(s)
All EU and non-EU citizens and stakeholders are welcome to contribute to this consultation. Contributions are sought from individuals, local, regional and national authorities, international and regional organisations, intergovernmental and non-governmental organisations, academic institutions, third countries, social partners and civil society.
Period of consultation
From 15/02/2016 to 09/05/2016
Objective of the consultation
The EU Drugs Strategy provides a political framework and priorities for actions in the field of drug policies for the period 2013-2020. It builds around two policy fields: drug demand reduction and drug supply reduction; and three cross-cutting themes: coordination, international cooperation and information, research, monitoring and evaluation.
The EU Drugs Strategy requests the Commission to initiate an external mid-term assessment by 2016, in view of preparing a second Action Plan for the period 2017-2020.
In the framework of this evaluation and following the Better Regulation Guidelines, the Commission is conducting a broad stakeholder consultation, including an open public consultation, as outlined also in the roadmap of the evaluation . The stakeholder consultation seeks to gather views from individual citizens, non-profit/private organisations, industry and from national/regional/local public administrations on all 5 objectives of the EU Drugs Strategy and corresponding actions of the Action Plan and on the key evaluation criteria: effectiveness, efficiency, relevance, coherence and EU value added. This public consultation will form part of the evidence base for the evaluation of the EU Drugs Strategy and Action Plan and the work ahead.
A Steering Group, made up all relevant Commission services and the European External Action Service (EEAS) chaired by DG HOME, is consulted regularly at all stages of this evaluation and it has approved the consultation strategy for this evaluation, as well as the questionnaire for the public consultation.
How to submit your contribution
You can contribute to this public consultation by filling in the online questionnaire which is available in English. You may pause at any time and continue later. Once you have submitted your answers, you can download a copy of your contribution.
Only responses received through the online questionnaire will be taken into account and included in the report summarising the responses.
In the interests of transparency, organisations (including, for example, NGOs, trade associations and commercial enterprises) are invited to provide the public with relevant information about themselves by registering in the Interest Representative Register and subscribing to its Code of Conduct.
If you are a Registered organisation, please indicate the name and address of your organisation and your Register ID number on the first page of your contribution. Your contribution will then be considered as representing the views of your organisation.
If your organisation is not registered, you have the opportunity to register now. Then return to this page to submit your contribution as a Registered organisation.
Responses from organisations not registered will be published separately.
The Commission asks organisations who wish to submit comments in the context of public consultations to provide the Commission and the public at large with information about whom and what they represent. If an organisation decides not to provide this information, it is the Commission's stated policy to list the contribution as part of the individual contributions. (Consultation Standards, see COM (2002) 704, and Communication on ETI Follow-up, see COM (2007) 127 of 21/03/2007).
Click here fore more information.
Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.
Thumbnail: Wikipedia Commons